<DOC>
	<DOC>NCT02255032</DOC>
	<brief_summary>The study is designed to evaluate the safety and efficacy of triamcinolone acetonide, CLS-TA, in subjects with macular edema following non-infectious uveitis. A single suprachoroidal injection of one of two doses of CLS-TA will each be evaluated in subjects with macular edema following non-infectious uveitis.</brief_summary>
	<brief_title>Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis</brief_title>
	<detailed_description>This is a Phase 2, randomized, masked, multicenter study to assess the safety and efficacy of two different doses of CLS-TA in the treatment of subjects with macular edema following non-infectious uveitis. Each subject will receive a single suprachoroidal injection of CLS-TA. The subjects enrolled in this study will be chosen from subjects with macular edema following non-infectious uveitis. A single injection will be administered via the Clearside microinjector into the suprachoroidal space. The dose injected will either be 4 mg or 0.8 mg of CLS-TA in a total volume of 100 Î¼L. The dose they receive will depend on what their randomization code dictates. Subjects will be monitored for safety and efficacy for approximately 8 weeks following treatment.</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Panuveitis</mesh_term>
	<mesh_term>Uveitis, Posterior</mesh_term>
	<mesh_term>Uveitis, Intermediate</mesh_term>
	<mesh_term>Pars Planitis</mesh_term>
	<mesh_term>Uveitis, Anterior</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>diagnosis of noninfectious uveitis diagnosis of macular edema associated with noninfectious uveitis any ocular trauma within the immediate 6 months prior to treatment any photocoagulation or cryotherapy in the 6 months prior to treatment any IVT injection of antiVEGF treatment in the 2 months prior to treatment any eye diseases other than uveitis and ME that could compromise central visual acuity any previous suprachoroidal injection of triamcinolone acetonide in the study eye</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>uveitis</keyword>
	<keyword>macular edema</keyword>
	<keyword>UME</keyword>
	<keyword>posterior uveitis</keyword>
	<keyword>anterior uveitis</keyword>
	<keyword>panuveitis</keyword>
	<keyword>intermediate uveitis</keyword>
	<keyword>noninfectious uveitis</keyword>
	<keyword>triamcinolone acetonide</keyword>
	<keyword>suprachoroidal space</keyword>
	<keyword>injection</keyword>
	<keyword>microneedle</keyword>
	<keyword>intravitreal injection</keyword>
	<keyword>corticosteroid</keyword>
	<keyword>CME</keyword>
	<keyword>choroid</keyword>
	<keyword>retina</keyword>
	<keyword>microinjection</keyword>
	<keyword>SCS</keyword>
</DOC>